Home » Stocks » Editas Medicine

Editas Medicine, Inc. (EDIT)

Stock Price: $35.32 USD 0.57 (1.64%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $35.54 +0.22 (0.62%) Aug 13, 7:13 PM

Stock Price Chart

Key Info

Market Cap 1.94B
Revenue (ttm) 32.60M
Net Income (ttm) -132.01M
Shares Out 62.27M
EPS (ttm) -2.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $35.32
Previous Close $34.75
Change ($) 0.57
Change (%) 1.64%
Day's Open 34.60
Day's Range 34.52 - 35.57
Day's Volume 447,426
52-Week Range 14.01 - 39.96

More Stats

Market Cap 1.94B
Enterprise Value 1.37B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 62.27M
Float 60.93M
EPS (basic) -2.51
EPS (diluted) -2.49
FCF / Share -1.42
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.40M
Short Ratio 10.09
Short % of Float 14.20%
Beta 1.98
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 59.58
PB Ratio 5.07
Revenue 32.60M
Operating Income -151.97M
Net Income -132.01M
Free Cash Flow -78.65M
Net Cash 569.92M
Net Cash / Share 10.36
Gross Margin -234.23%
Operating Margin -466.09%
Profit Margin -404.90%
FCF Margin -241.23%
ROA -18.79%
ROE -42.59%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 5
Overweight 1
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$41.88*
(18.57% upside)
Low
28.0
Current: $35.32
High
65.0
Target: 41.88
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue20.5331.9413.736.051.63-
Revenue Growth-35.71%132.64%126.8%271.58%--
Gross Profit20.5331.9413.736.051.63-
Operating Income-141-114-120-97.19-35.31-12.72
Net Income-134-110-120-97.18-72.90-13.69
Shares Outstanding49.9847.1040.3232.222.571.12
Earnings Per Share-2.68-2.33-2.98-3.02-28.55-12.46
Operating Cash Flow-40.67-45.71-9.42-50.25-5.44-8.66
Capital Expenditures-6.07-4.72-2.04-3.47-1.43-1.22
Free Cash Flow-46.73-50.42-11.46-53.72-6.87-9.87
Cash & Equivalents45736932918514310.62
Total Debt29.0832.4240.9345.10-0.41
Net Cash / Debt42833728814014310.21
Assets50942037322914912.19
Liabilities24618416594.5832.566.71
Book Value262236208135-83.11-15.29
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Editas Medicine, Inc.
Country United States
Employees 208
CEO Cynthia L. Collins

Stock Information

Ticker Symbol EDIT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: EDIT
IPO Date February 3, 2016

Description

Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.